(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients

Trial Profile

(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Betrixaban (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms APEX
  • Sponsors Portola Pharmaceuticals
  • Most Recent Events

    • 30 Aug 2017 Results of a post-hoc substudy of Apex trial evaluating the modulation of the treatment effect of betrixaban versus standard duration enoxaparin as a function of D-dimer concentrations, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
    • 30 Aug 2017 Results analysing the potential effect of patient characteristics on population pharmacokinetics and exposure response relationships for acute medically ill patients, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
    • 30 Aug 2017 Results assessing predictive value of N-terminal pro B type natriuretic peptide for stroke and its impact on the treatment effect, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top